Clinical reference Biomarker Directory
Back to directory

SS-B/La Antibodies

Established

SS-B/La usually accompanies SS-A/Ro in Sjogren's syndrome; the combination is more diagnostically specific than either alone.

Also known as Anti-SS-B anti-La antibody
In plain language

This antibody usually shows up together with the SS-A/Ro antibody in Sjogren's syndrome, and having both together makes the diagnosis more certain. It carries a similar, slightly lower pregnancy-related heart risk to the baby as SS-A/Ro.

Biomarker & context

Anti-SS-B/La antibodies usually accompany SS-A/Ro antibodies in Sjogren's syndrome, and the combination of both antibodies is more specific for the diagnosis than either antibody alone.

What it indicates

Positive SS-B/La, typically alongside SS-A/Ro, supports Sjogren's syndrome diagnosis; it carries a similar, though somewhat lower, congenital heart block risk in pregnancy compared to SS-A/Ro alone.

Diagnosis & clinical testing

Measured via immunoassay as part of the same ENA panel as SS-A/Ro; isolated SS-B/La positivity without SS-A/Ro is uncommon and its clinical significance is less well established than the more typical combined pattern.

Guiding treatment

As with SS-A/Ro, pregnant patients with SS-B/La positivity are monitored with serial fetal echocardiography for congenital heart block risk, usually as part of the same monitoring protocol used for SS-A/Ro-positive pregnancies.

Clinical significance

Carries a similar, somewhat lower, congenital heart block risk in pregnancy compared to SS-A/Ro.

References
  1. General rheumatology reference literature on SS-A/Ro and SS-B/La antibody patterns in Sjogren's syndrome.